Book Value per Share: Belite Bio, Inc. (BLTE)

Graphic logo of Belite Bio Corp (BLTE)

The price trajectory of Belite Bio, Inc (BLTE) demonstrates the current indicator 19.40. A team of elite ophthalmology researchers, attracted by ambitious goals and equity options, is developing treatments against blindness. This innovative therapy method provides a competitive moat and a chance for market leadership following certification. Business efficiency is bolstered by streamlined international cold-chain logistics, ensuring cargo integrity and high profitability.

Belite Bio (BLTE): Share Book Value from 04/28/2023 to 10/27/2026

Belite Bio Pharma - analytical breakdowns and key metrics (BLTE)

- price and consensus price forecast:
Stock Quotes Belite Bio Inc|BLTE - Analyst Forecast Prices
- market capitalization data:
Market Capitalization Belite Bio, Inc.|BLTE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Belite Bio|BLTE - Net Asset Value|Market Capitalization to Book Value Ratio belitebio.com|BLTE - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Belite Bio, Inc|BLTE - Long-Term Debt to Capital|Short-Term Debt to Equity Belite Bio, Inc|BLTE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Belite Bio, Inc.
Fundamental company valuation:Belite Bio - BLTE
Manufactured products of Belite Bio, Inc

For Belite Bio, Inc (BLTE), this indicator serves as a measure of the business's intrinsic value during the completion of clinical trials. By calculating the ratio of equity to the number of shares, this book value per share chart demonstrates the actual volume of assets per share. The metric reflects the market consensus on the efficiency of profit reinvestment. Amidst advance confidence in management, the indicator reveals the risk of a value trap. The fundamental stability of Belite Bio, Inc (BLTE) now depends directly on regulatory decisions.

Competitors of Belite Bio, Inc (BLTE)

Accounting Value per Share Alcon Vision ALC|BLCO - Book Price of a Share|Book Value per Share GKOS|APLS (apellis.com) - Net Asset Value per Share|Net Assets per Single Share Ocular Therapeutix, Inc. OCUL|Share Book Value Harrow Inc|Viridian Pharma (VRDN) - Book Value per Share|Accounting Value of a Share LENZ Corp (LENZ)|Book Value per Share OCS (Oculis AG)|eyepointpharma.com - Book Value per Share|Net Assets per Single Share Kodiak Sciences (KOD)|ALDX: Accounting Value of a Share|KALA (kalarx.com) - Net Assets per Single Share|Opus Genetics (IRD) - Accounting Value per Share|OKYO (OKYO Pharma Ltd) - Book Value per Share|Book Value per Share Adverum (ADVM)|Outlook Therapeutics, Inc. (OTLK) - Accounting Value per Share|Accounting Value of a Share Clearside Biomedical Inc (CLSD)|NBY: Book Value per Share|KPRX - Net Asset Value per Share|ALIM (Alimera) - Accounting Value per Share|EYEN - Net Asset Value per Share|Book Value per Share GHSI|OCUP (Ocuphire Pharma Inc) - Net Asset Value per Share|OPT: Net Assets per Single Share